Pharmacological targeting of the IL-17/neutrophil axis attenuates calcific deposits in rat models of calciphylaxis

  • 0Division of Cardiology, Department of Medicine, David Geffen School of Medicine.

|

|

Summary

This summary is machine-generated.

Calciphylaxis involves skin calcification driven by inflammation and immune cells. Targeting interleukin-17 (IL-17) and neutrophils shows promise in reducing calcific deposits in animal models.

Area Of Science

  • Dermatology
  • Immunology
  • Pathobiology

Background

  • Calciphylaxis is a rare, severe condition with poor survival and unclear mechanisms.
  • Ectopic calcification in skin and blood vessels characterizes this disorder.

Purpose Of The Study

  • To investigate the pathobiology of calciphylaxis using animal models.
  • To explore the role of inflammation and the immune system in disease development.

Main Methods

  • Developed animal models mimicking human calciphylaxis.
  • Assessed the impact of immune cell activation, immunosuppressants, and targeted therapies.
  • Analyzed cytokine and enzyme expression in affected tissues.

Main Results

  • Cutaneous calcification was preceded by inflammatory cell infiltration.
  • Immune cell-deficient rodents were resistant to calcification.
  • IL-17 and neutrophils were identified as key mediators.
  • Targeting IL-17 or neutrophils reduced calcific deposits.

Conclusions

  • Local inflammation, hypercalcemia, and hyperphosphatemia contribute to calciphylaxis.
  • The immune system, particularly the IL-17/neutrophil axis, plays a critical role.
  • Therapeutic strategies targeting these pathways may be beneficial.